Kinaxis Inc. (TSE:KXS – Get Free Report) has earned an average recommendation of “Moderate Buy” from the six ratings firms that are presently covering the company, Marketbeat reports. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. The average 1 year target price among brokerages that have issued ratings on the stock in the last year is C$195.00.
KXS has been the subject of several research analyst reports. CIBC lowered their target price on shares of Kinaxis from C$175.00 to C$170.00 in a report on Friday, February 28th. Royal Bank of Canada set a C$210.00 price objective on Kinaxis and gave the stock an “outperform” rating in a report on Friday, March 21st.
View Our Latest Stock Analysis on KXS
Insiders Place Their Bets
Kinaxis Trading Down 0.9 %
TSE:KXS opened at C$155.24 on Tuesday. The company has a debt-to-equity ratio of 12.12, a quick ratio of 2.29 and a current ratio of 1.89. Kinaxis has a 1 year low of C$132.93 and a 1 year high of C$190.17. The stock has a market cap of C$3.12 billion, a P/E ratio of 154.07, a P/E/G ratio of 3.60 and a beta of 0.78. The stock has a 50-day simple moving average of C$163.32 and a 200-day simple moving average of C$166.16.
Kinaxis Company Profile
Kinaxis Inc provides cloud-based subscription software for supply chain operations in the United States, Europe, Asia, and Canada. It offers RapidResponse, a cloud-based platform, which provides advanced planning, sales and operation planning, supply and demand planning, inventory management, and command and control center services.
See Also
- Five stocks we like better than Kinaxis
- The 3 Best Retail Stocks to Shop for in August
- MarketBeat Week in Review – 03/24 – 03/28
- What Does a Gap Up Mean in Stocks? How to Play the Gap
- Should You Buy UPS Stock Now? Deep Dive Into Its 5-Year Low
- Dividend Screener: How to Evaluate Dividend Stocks Before Buying
- 4 Healthcare Stocks With Massive Gains—and More to Come
Receive News & Ratings for Kinaxis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kinaxis and related companies with MarketBeat.com's FREE daily email newsletter.